CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients - PharmaTimes Positive opinion issued for marketing authorisation extension

#oncology #CHMP #SC #Rybrevant #amivantamab #EGFRmutatedNSCLC #EGFRmutatedNSCLCpatients #marketingauthorisationextension #subcutaneousformulation #nonsmallcelllungcancer #NSCLC #lungcancer #JanssenCilag #phase3PALOMA3study #SCamivantamab #MedicalOncology
pharmatimes.com/news/chmp-re...